Hafnarfirði, Iceland, Dec 12, 2007 - (Hugin via ABN Newswire) - Reykjavik, Iceland, 12 December 2007 -- Actavis Group, the international generic pharmaceuticals company has marketed its first own brand products in the Italian market.

Italy, population 58 million, is the fourth largest European pharmaceutical market which Actavis enters. The Italian generics market has expanded at double-digit rates in recent years with company branded generic products especially showing significant growth recently.

The Company recently opened offices in Saronno, just north of Milan, close to the Malpensa airport.

With close to 200 registration processes running, Actavis Italy has already launched about 20 products. The initial launch was Amoxicillin (antibiotic) in October, followed by Calcio carbonato (osteoporosis), Citalopram (antidepressant), Diazepam (central nervous system), Gentamicine (antibiotic), Gentamicine/ Betamethasone (dermatologic), Bromazepam (central nervous system), Lormetazepam (central nervous system), Pupybel (eye care) and Triazolam (insomnia) in November. Scheduled December launches include Ceftriaxone (antibiotic), AmoxiClav (antibiotic), Carvedilol (cardiovascular), Aciclovir (antiviral) Nimesulide (FANS) and Ranitidine (gastrointestinal).

Actavis' Third party sales division, Medis, entered the Italian market in 2004, marketing its products through other pharmaceutical companies. Medis is currently selling 13 products into Italy, and a few major patent expiry launches are coming up at the end of the year, including Ramipril and Ramipril HCT (cardiovascular).

Svend Andersen, Executive Vice President, WEMEA, said: "Actavis has the scale to support a price conscious Italian market and more importantly the high quality products that Italians require. We expect to launch 74 products next year and will support it by full infrastructure and sales force."

Enquiries Actavis Italy Paolo Saraceno Communication Officer Tel: (+39) 02 96367301 E-mail: Psaraceno@actavis.com

Actavis Group Hjördís Árnadóttir Director - External communications Tel: (+354) 535 2300 / 840 7476 E-mail: harnadottir@actavis.com

About Actavis Group Actavis is one of the world's leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals. Based in Iceland, the company has operations in 40 countries, with 11,000 employees. Actavis expects 2007 sales to total EUR1.6bn, with approximately one-third of these sales coming from the United States, the company's single largest market.

Further information about Actavis Group can be found on the web: www.actavis.com

Any statements contained in this presentation that refer to Actavis' estimated or anticipated future results or future activities are forward-looking statements which reflect the Company's current analysis of existing trends, information and plans. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially depending on factors such as the availability of resources, the timing and effect of regulatory actions, the success of new products, the strength of competition, the success of research and development issues, unexpected contract breaches or terminations, exposure to product liability and other lawsuits, the effect of currency fluctuations and other factors.

Copyright © Hugin ASA 2007. All rights reserved.

Actavis

http://www.actavis.com

ISIN: IS0000000420

Stock Identifier: ICEX.ACT